help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

The Oncologist, Vol. 13, No. 4, 410-414, April 2008; doi:10.1634/theoncologist.2007-0224
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vergote, I.
Right arrow Articles by Berteloot, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vergote, I.
Right arrow Articles by Berteloot, P.

Gynecologic Oncology

Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View

Ignace Vergote, Frederic Amant, Karin Leunen, Isabelle Cadron, Toon Van Gorp, Patrick Neven, Patrick Berteloot

Division of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium

Key Words. Ovarian neoplasms • Chemotherapy • Intraperitoneal

Correspondence: Ignace Vergote, M.D., Ph.D., Department of Gynaecological Oncology, Division Obstetrics & Gynaecology, UZ-Leuven, Herestraat 49, 3000 Leuven, Belgium. Telephone: 32-16344635; Fax: 32-16344629; e-mail: Ignace.Vergote{at}uz.kuleuven.ac.be

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Objectives. In this paper we wish to present the reasons why i.p. chemotherapy cannot be accepted as standard of care for first-line systemic treatment of advanced ovarian carcinoma.

Methods. The recent literature on i.p. chemotherapy is critically reviewed. All possible arguments against i.p. chemotherapy are reviewed.

Conclusions. Intraperitoneal chemotherapy is associated with a higher toxicity rate than i.v. chemotherapy. For this reason, none of the regimens investigated in the three Gynecologic Oncology Group (GOG) studies can be used as standard treatment outside clinical protocols. The trials on i.p. chemotherapy have suggested a survival difference. However, in the two most recent trials, i.p. chemotherapy or not was not the only research question because different schedules and dosages were used. In addition, the significance of the most recent GOG 172 study was only weak (p = .03), and the result was nonsignificant for progression-free survival. Intraperitoneal chemotherapy should be used only in the context of properly designed clinical trials. These trials must either assess i.p. therapy in comparison with the standard treatment or address the issue of route of administration for equivalent dosages and schedules of the same drugs, and not a mosaic of these questions. In addition, these trials should investigate i.p. regimens that are less toxic than the regimens used in the three GOG trials, and which can be combined with molecular targeted therapies.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.